APA (7th ed.) Citation

A, O., CN, H., T, K., M, T., & S, O. (2026). Anlotinib plus penpulimab: A new contender in first-line therapy for unresectable hepatocellular carcinoma. Journal of gastrointestinal oncology, 17(2), 114. https://doi.org/10.21037/jgo-2025-aw-857

Chicago Style (17th ed.) Citation

A, Ono, Hayes CN, Kawaoka T, Tsuge M, and Oka S. "Anlotinib Plus Penpulimab: A New Contender in First-line Therapy for Unresectable Hepatocellular Carcinoma." Journal of Gastrointestinal Oncology 17, no. 2 (2026): 114. https://doi.org/10.21037/jgo-2025-aw-857.

MLA (9th ed.) Citation

A, Ono, et al. "Anlotinib Plus Penpulimab: A New Contender in First-line Therapy for Unresectable Hepatocellular Carcinoma." Journal of Gastrointestinal Oncology, vol. 17, no. 2, 2026, p. 114, https://doi.org/10.21037/jgo-2025-aw-857.